Nowadays, genetic testing is offered primarily to patients with early onset breast/ovarian cancer (<45 years) or when a strong family history is present, and it primarily involves analysis of BRCA1 and BRCA2 genes. This evidence concerns the gene BRCA1 and ovarian cancer.